Thermo Fisher Scientific Inc. announced the completion of its acquisition of Sanofi’s sterile fill-finish and packaging facility in Ridgefield, New Jersey, expanding its strategic partnership with Sanofi and bolstering U.S. drug manufacturing capacity. The financial terms of the deal were not disclosed.
The Ridgefield site will now operate under Thermo Fisher’s Laboratory Products and Biopharma Services segment, continuing to manufacture Sanofi’s therapies while also serving other pharmaceutical and biotech clients facing increased demand for U.S.-based manufacturing.
Marc N. Casper, Thermo Fisher’s chairman, president, and CEO, expressed enthusiasm about the acquisition, noting the addition of over 200 experienced employees and the enhancement of the company’s U.S. manufacturing footprint.
This acquisition strengthens Thermo Fisher’s existing sterile fill-finish network, complementing its facilities in Greenville, North Carolina, and Plainville, Massachusetts. These sites support the company’s Accelerator Drug Development 360° CDMO and CRO solutions, designed to accelerate drug development and delivery for emerging biotech and biopharma firms.
The Ridgefield facility acquisition marks a significant step in Thermo Fisher’s efforts to expand its manufacturing capabilities and support innovation in the pharmaceutical industry.